Funded in part by Natreon, Inc.
Ashwagandha and Shatavari Extracts Dose-Dependently Reduce Menopause Symptoms, Vascular Dysfunction, and Bone Resorption in Postmenopausal Women: A Randomized, Double-Blind, Placebo-Controlled Study
Pingali U, Nutalapati C, Wang Y
Journal of menopausal medicine · 9 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Randomized controlled trial (classified by our AI screen)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Industry funded
- Government
- National Institute of Dental and Craniofacial Research
- Company
- Natreon, Inc.
- Government
- NIDCR NIH HHS
- Grants
- National Institute of Dental and Craniofacial Research (K01 DE032775)
Based on 3 listed funder(s) and full-text disclosure statement.
Publication
- Published
- 2025-01-01 · J Menopausal Med · vol. 31 · issue 1 · p. 21
- Cited
- 8 citations · more than 98% of similar papers · 9.2× the field average
- Impact
- Top 10% most cited in its field
- References
- 47 works
- Access
- Open access (free to publish) · CC-BY-NC
- Research areas
- Phytochemicals and Medicinal Plants · Pharmacological Effects of Medicinal Plants · Menopause: Health Impacts and Treatments
- Keywords
- Medicine, Placebo, Menopause, Resorption, Postmenopausal women, Randomized controlled trial, Internal medicine, Physiology, Alternative medicine, Pathology
3 authors
From IN, US
- Usharani PingaliNizam's Institute of Medical Sciences
- Chandrasekhar NutalapatiNizam's Institute of Medical Sciences
- Yan WangLos Angeles County Department of Public Health
Abstract
Objectives
In this study, we investigate the effects of dietary supplementation with standardized aqueous extracts of shatavari (Asparagus racemosus, Ar), ashwagandha (Withania somnifera, Ws), or their combination on menopausal symptoms, vascular dysfunction, bone turnover, and serum concentrations of inflammatory and oxidative stress markers in postmenopausal women.
Methods
Postmenopausal women aged 40-55 were enrolled in a double-blind randomized study to receive one of six treatments: placebo, Ar 250 mg/500 mg, Ws 250 mg/500 mg, or 500 mg extract combining Ar 250 mg and Ws 250 mg. Primary outcomes were changes in the menopause-specific quality of life (MENQOL) questionnaire, bone mineral density/bone turnover markers (BTMs), and reflection index (RI) after 24 weeks. Secondary outcomes included changes in serum inflammatory and oxidative stress markers, and evaluation of supplement safety and tolerability.
Results
Supplemented groups showed significant dose-dependent decrease MENQOL and RI compared with placebo (P P P < 0.0001) were also observed.
Conclusions
Daily supplementation with Ws or Ar extracts dose-dependently reduces menopausal symptoms, vascular dysfunction, bone turnover/resorption, and estrogen deficiency-related inflammation and oxidative stress in postmenopausal women.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY-NC).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.